Key Insights

Highlights

Treatment Research

2 treatments under study, led by D1d14 Lansoprazole Clarithromycin Amoxicillin

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 4 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT01607918Phase 4UnknownPrimary

Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy 10 Days in the First Line Therapy

Showing all 1 trials

Research Network

Common Treatments

  • D1d14 Lansoprazole Clarithromycin Amoxicillin1
  • D1d5 Lansoprazole Amoxicillin D6d10 Lansoprazoleclarithromycin Metronidazole1

Active Sponsors

  • National Taiwan University Hospital1

Top Investigators

Activity Timeline